Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

810 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team. Podzamczer D, et al. Among authors: ferrer e. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47. doi: 10.1097/QAI.0b013e31802bf122. J Acquir Immune Defic Syndr. 2007. PMID: 17106274 Clinical Trial.
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J. Podzamczer D, et al. Among authors: ferrer e. Antivir Ther. 2002 Jun;7(2):81-90. Antivir Ther. 2002. PMID: 12212928 Clinical Trial.
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
Ferrer E, Podzamczer D, Arnedo M, Fumero E, McKenna P, Rinehart A, Pérez JL, Barberá MJ, Pumarola T, Gatell JM, Gudiol F; Combine Study Team. Ferrer E, et al. J Infect Dis. 2003 Feb 15;187(4):687-90. doi: 10.1086/367987. Epub 2003 Jan 29. J Infect Dis. 2003. PMID: 12599088 Clinical Trial.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team. Martínez E, et al. Among authors: ferrer e. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5. J Acquir Immune Defic Syndr. 2009. PMID: 19398921 Clinical Trial.
810 results